TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03544515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling
Description: Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling
Description: Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Er,Cr:YSGG
Description: Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
Study: NCT03175172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Administered by IV infusion over approximately 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by IV infusion over approximately 30 minutes.
Study: NCT03840421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and fluorouracil
Description: Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
Study: NCT02990650

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Task Training with therapist guarding support
Description: Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance task training with robotic guarding support
Description: Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challneged balance task training with robotic guarding support
Description: Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot
Study: NCT02818517

Intervention type: OTHER
Intervention: ACE inhibitors
Description: Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.

Intervention type: OTHER
Intervention: beta blockers
Description: Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
Study: NCT04097652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06
Description: Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
Study: NCT03840421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
Study: NCT00737035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Healthcare Communication Application
Description: The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Web sites
Description: Only publicly available Web sites on parenting, child development, and trauma will be used.
Study: NCT00507338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: early PCI for NSTEMI; primary PCI for STEMI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: early PCI for NSTEMI; primary PCI for STEMI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: early PCI for NSTEMI; primary PCI for STEMI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: early PCI for NSTEMI; primary PCI for STEMI
Study: NCT03815136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
Study: NCT00706381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carb meal
Description: 600 calorie meal containing 100% carbohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV and/or oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV and/or oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV and/or oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV and/or oral placebo
Study: NCT02664363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRvIII CAR T cells
Description: The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
Study: NCT01077466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: 300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
Study: NCT02251873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV + RTV (low dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV + RTV (high dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddl
Study: NCT00115297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
Study: NCT04633018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AsthmaMD mobile application
Description: asthma management app with Spanish-language user interface
Study: NCT02508753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101/tazobactam
Description: 1000/500 mg single IV dose administered over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101/tazobactam
Description: 3000/1500 mg single IV dose administered over 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
Study: NCT01915693

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
Study: NCT01172821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo that represents BI drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo that represents comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo that represents comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® low dose
Description: IMP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo that represents BI drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® high dose
Description: IMP
Study: NCT04633018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Asthma management without the app
Study: NCT01172821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mcg salmeterol HFA MDI
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo that represents comparator
Study: NCT01215513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study: NCT03714360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0,9%
Description: Sodium Chloride 0,9%
Study: NCT00249691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate + Cognitive Behavioral Therapy
Description: Topiramate up to 300 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: Placebo twice a day
Study: NCT04072016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Aqueous Microshunt
Description: The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
Study: NCT00644449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR (Zithromax; compound: CP-62,993)
Description: azithromycin 2.0 g by mouth in the form of a slurry for 1 dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: 500 mg (two 250 mg capsules) by mouth once daily for 7 days
Study: NCT03145831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somavaratan
Description: All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
Study: NCT01708629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
Study: NCT01844128

Intervention type: DIETARY_SUPPLEMENT
Intervention: weight loss
Study: NCT01708629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered SC
Study: NCT05810558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glycine powder air-powered debridement
Description: The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic instrumentation
Description: The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
Study: NCT03939299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT
Description: Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
Study: NCT04054505

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months
Study: NCT01418482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border Ag
Description: a silver dressing
Study: NCT00551096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
Study: NCT04054505

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months
Study: NCT01374997

Intervention type: OTHER
Group type: OTHER
Intervention: micromethod from samples taken from blood spots on filter paper
Description: a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
Study: NCT03954665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 km time trial
Description: 10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30s Wingate
Description: 30s all-out test to measure peak power output

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: Supplement containing exogenous ketone salts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline 10 km time trial
Description: A baseline 10 km Cycling time trial test will be conducted

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline 30s Wingate
Description: A baseline 30s all-out test to measure peak power output
Study: NCT04338074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 2 tablets p.o. three times per day x 5 days
Study: NCT02185092

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: probiotic supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: placebo
Study: NCT04803071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group of n-pufas improving cognitive formula
Description: Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: General fish oil formula product adjuvant treatment control group
Description: The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo assisted treatment group
Description: Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
Study: NCT02849041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical imaging
Description: Low-dose CT-scanner

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Identification of Circulating Tumor Cells
Description: Research of circulating tumor cells in blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychological Questionnaires
Description: The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells.
Study: NCT02133469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)
Description: injection 0.5 mL, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib Vaccine
Description: Single Dose
Study: NCT01132352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study: NCT02402595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923
Study: NCT01930864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin up to 2500mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan 350 mg/m² IV q21d
Study: NCT04153331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Description: Patient included in emergency with a nasal swab
Study: NCT00925041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vedera KXS
Description: one treatment with the Vedera KXS
Study: NCT02402595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT00939770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies